Avaliação do perfil metabólico de camundongos obesos tratados com uma nanoformulação lipídica de Esclareol

• Ano de defesa: 2017
• Autor(a) principal: Gabriela Cavazza Cerri
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Fisiologia e Farmacologia; Farmacologia; Fisiologia
• Link de acesso: http://hdl.handle.net/1843/BUBD-AP7L8B

Sclareol is a diterpene isolated from Salvia sclarea. Sclareol has been used as ingredient in cosmetics. Furthermore, this diterpene has been shown (i) to activate cytotoxic and cytostatic pathways against leukemia cell lines, (ii) anti-inflammatory and (iii) antioxidant properties. However, Sclareol has low bioavailability due to its high lipophilicity, therefore the use of Sclareol in vivo is hampered. This study aim was to evaluate the metabolic effects of Sclareol in different formulations (lipid nanoparticle and free) of mice with high fat diet induced metabolic syndrome. Methods: Swiss male mice were initially divided into two groups throughout 4 weeks: standard diet (ST) and high fat diet (HF). Subsequently, insulin sensitivity test and glucose tolerance test were performed. Each group was divided into 3 treatments subgroups: free sclareol (Sc), lipid nanoparticle of sclareol (L-Sc) and empty lipid nanoparticle (L). The sclareol (free and lipid nanoparticle) were administered intraperitoneally in 300l and 1mg/kg dose. Treatments were performed for 30 days. Afterward, the glucose tolerance test and insulin sensitivity test were performed. The animals were euthanized by decapitation, blood and target organs were collected and stored. Results: During treatment body weight reduced. Significant improvement of glycemic profile and HDL levels increased in HF L-Sc mice was shown. It was also observed adiposity reduction and decreased expression of NF-KB, MCP-1 and SREBP-1 in HF L-Sc mice compared with HF L mice. Conclusion: The lipid nanoparticle of sclareol improved metabolic parameters in obese mice. Sclareol when associated with lipid nanoparticle may be a new therapeutic strategy to assist in the treatment of diseases associated with metabolic disorders.